AIxCrypto Holdings, BitMart launch co‑branded virtual prepaid card to bridge Web3 payments
- AIxCrypto Holdings partners with BitMart to launch a co‑branded virtual prepaid card for everyday online and wallet payments.
- AIxCrypto supplies community reach, brand participation and marketing; BitMart manages issuance, onboarding, customer support and compliance.
- AIxCrypto calls the card part of its AIxC/BesTrade roadmap, but warns outcomes depend on regulatory, licensing and timing risks.
AIxCrypto, BitMart roll out co‑branded virtual prepaid card to bridge Web3 and everyday payments
AIxCrypto Holdings is partnering with crypto exchange BitMart to launch a co‑branded virtual prepaid card that aims to make blockchain‑linked payments usable for routine online and digital‑wallet transactions. The card is designed for everyday digital payments and integrates with major wallet networks, giving eligible members of AIxCrypto’s global community a route to spend in familiar merchant environments subject to regional availability and terms.
The agreement makes a clear division of labor: AIxCrypto contributes community reach, brand participation and marketing channels, while BitMart acts as the exclusive operator and is solely responsible for card issuance, user onboarding, customer support and the entire payments infrastructure. BitMart also bears responsibility for regulatory compliance, licensing and adherence to payment‑network rules, reflecting a deliberate separation between AIxCrypto’s ecosystem engagement role and BitMart’s regulated financial operations.
AIxCrypto frames the initiative as part of a broader strategy to deliver practical utility and scalable, compliance‑minded products that bridge Web2 and Web3. The company highlights its BesTrade DeAI Agent and wider AIxC ecosystem as roadmap components that pair AI capabilities with blockchain features, while noting that final product terms — rollout timing, eligibility, transaction limits, fees and supported currencies — will be disclosed by BitMart in line with regional laws, licensing timelines and consumer protection standards.
Forward‑looking statements and risk caveats
The announcement contains customary forward‑looking statements under the Private Securities Litigation Reform Act, and AIxCrypto warns that expectations about future actions, results and timelines are subject to risks and uncertainties, including regulatory developments and the pace of licensing for payment products in different jurisdictions.
Industry context: payments as the bridge to mainstream crypto use
The tie‑up follows a broader industry trend in which crypto firms partner with licensed payment operators to convert digital assets into spendable balances and to offer consumers familiar card rails. Market observers say such partnerships aim to provide real‑world utility for crypto ecosystems while limiting regulatory exposure for project founders by placing issuance and compliance with established financial firms.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…